Altimmune to Announce Second Quarter 2020 Financial Results on August 12
Altimmune, Inc. (Nasdaq: ALT) announced it will report its financial results for Q2 2020 before the market opens on August 12, 2020, and will host a conference call at 8:30 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced it will report its financial results for Q2 2020 before the market opens on August 12, 2020, and will host a conference call at 8:30 am ET. The company is focused on developing intranasal vaccines and immune modulating therapies, including those for COVID-19 and liver diseases. Notable products in their pipeline include AdCOVID™, NasoShield™, and ALT-801. Investors can access the conference call via the provided webcast link.
Positive
- Diverse pipeline with intranasal vaccines targeting COVID-19 and other diseases.
- Upcoming financial results may provide key insights for investors.
Negative
- Still in clinical stage, indicating potential delays in product commercialization.
Details
News Market Reaction – ALT
The recorded move for ALT in the trading session of this news was -3.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a conference call on Wednesday, August 12, 2020.
| Conference Call Details | |
| Date: | Wednesday, August 12 |
| Time: | 8:30 am Eastern Time |
| Domestic: | 877-423-9813 |
| International: | 201-689-8573 |
| Conference ID: | 13706947 |
| Webcast: | http://public.viavid.com/index.php?id=140748 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
| Investor Contacts: | |
| Will Brown | Ashley R. Robinson |
| Chief Financial Officer | LifeSci Advisors, LLC |
| Phone: 240-654-1450 | 617-430-7577 |
| wbrown@altimmune.com | arr@lifesciadvisors.com |
| Media Contacts: | |
| Warren Rizzi | |
| Sard Verbinnen & Co. | |
| Phone: 212-687-8080 | |
| altimmune-svc@sardverb.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.